Tools and resources
ASCO living guideline on Treatment of multiple myeloma
ASCO’s living guideline covers treatment across the myeloma pathway. This update focuses on relapsed or refractory myeloma, recommending ciltacabtagene autoleucel and teclistamab plus daratumumab as preferred options at first relapse for eligible patients who have not previously received BCMA-directed treatment.
ASCO GuidelineMyeloma Treatment Scheduler (MyeTx)
MyeTxScheduler (MyeTx) is a free online tool that helps healthcare professionals create clear, adaptable myeloma treatment schedules to support patient understanding and medication management.
BSH guideline on Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics
Read the British Society for Haematology guideline on early diagnosis of AL amyloidosis, including when to suspect it and when urgent haematology review may be needed.
BSH GuidelineDeveloping a business case for a Myeloma Clinical Nurse Specialist
A practical guide to help healthcare professionals develop a business case for a Myeloma or Haematology Clinical Nurse Specialist, including evidence, financial planning, and sample job description and job plan tools.
Digital Infosession: To transplant or not to transplant – that is the question
In the seventh co-partnered digital infosession from Myeloma UK and UKMS, chaired by Dr Jennifer Travers, clinicians discuss practical approaches to transplant and non-transplant decision making in myeloma, with a focus on shared decision making and real-world case discussion.
Reducing language barriers: Patient Infosheet for your practice
Download a printable infosheet to help people living with myeloma find Myeloma UK support in multiple languages, including via telephone interpretation.
GP Diagnostic Tool for Wales
Wales-adapted myeloma diagnostic tool to support GPs with recognising symptoms, interpreting tests and making timely referrals.
GP Myeloma Diagnostic Tool in Welsh
Welsh-language myeloma diagnostic tool for primary care, with guidance on tests, interpretation and referral.
Amyloidosis diagnosis pathway
Developed by Myeloma Patients Europe (MPE), this visual pathway outlines key signs, symptoms and investigations to support early diagnosis of AL amyloidosis.
Digital Infosession: Keeping an eye on belantamab mafodotin – mitigating ocular toxicities
In the sixth co-partnered digital infosession from Myeloma UK and UKMS, held on 15 October 2025 and chaired by Dr Jennifer Travers, leading clinicians explored the ocular toxicities associated with belantamab mafodotin (Blenrep®). The session focused on recognising, monitoring and managing eye-related side effects to support safer and more effective treatment delivery.
- 1